April 16 (Reuters) - Sartorius Stedim Biotech SA STDM.PA:
PUBLISHES UNAUDITED FIRST QUARTER RESULTS FOR 2025
Q1 SALES AT 745 MILLION EUROS, UP 10.4 PERCENT
FY 2025 GUIDANCE: SALES REVENUE INCREASE OF ABOUT 7%,UNDERLYING EBITDA MARGIN OF AROUND 30 TO 31 %
Q1 UNDERLYING EBITDA AT 229 MILLION EUROS, EBITDA MARGIN AT 30.8 PERCENT
Q1 NET PROFIT OF 85 MILLION EUROS
OUTLOOK 2025: RATIO OF CAPITAL EXPENDITURE TO SALES REVENUE EXPECTED TO BE AROUND 13 %
Source text: ID:nEQ41J5mya
Further company coverage: STDM.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 785 110;))